Affinergy has announced that it will be presenting at
Medtech Insight's Prestigious "Investment In Innovation (In3): A
Preview of Early-Stage Medical Technology Companies" Conference,
taking place June 14-15, 2005 at The Palace Hotel in San Francisco,
CA.
Affinergy, Inc., a Duke University spinout, develops site-specific biological & drug delivery systems using biofriendly binders that selectively adhere to proteins, drugs, cells, and other biomaterial surfaces in order to kickstart biology toward an intended outcome. Affinergy is focused in the orthopedic and biologic drug delivery markets with a growing interest in cardiovascular applications. Affinergy's technology was patented at Duke University and has been incubated at Becton Dickinson's research center in Research Triangle Park, North Carolina.
Affinergy was awarded 2005 Technology Innovation of the Year by Frost & Sullivan in the category of Medical Device Coatings. The award cited the biofriendly system of Affinergy which has the potential to "become an industry standard" for medical device coatings.
"Affinergy looks forward to meeting new Partners and Investors from a broad spectrum of markets at the Investment in Innovation Conference," said Peyton Anderson, CEO of Affinergy. "We are experiencing rapid growth fueled by Partnerships, grant funding, and early in vivo successes. Over the past year, we have validated our systems in vitro and in vivo as well as secured multiple partnerships with large medical device companies. We look forward to expanding upon that strong foundation by forming new collaborations."
Affinergy's "Interfacial Biomaterials" (IFBMs) are modular structures that include 2 functional peptides:
-- one selectively binds to a specific biological material
-- one selectively binds to a target surface (biological or synthetic)
The two peptides are joined through a proprietary linker technology that offers unique capabilities such as cleavability or cross-linking. Affinergy is building and patenting a "library" of peptides that bind with high affinity and high selectivity to synthetic and bioactive materials that are widely used in the biomedical and therapeutic industries.
Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "Investment In Innovation" conference or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512, e-mail kristy@medtechinsight.com, or visit www.medtechinsight.com.
Affinergy, Inc., a Duke University spinout, develops site-specific biological & drug delivery systems using biofriendly binders that selectively adhere to proteins, drugs, cells, and other biomaterial surfaces in order to kickstart biology toward an intended outcome. Affinergy is focused in the orthopedic and biologic drug delivery markets with a growing interest in cardiovascular applications. Affinergy's technology was patented at Duke University and has been incubated at Becton Dickinson's research center in Research Triangle Park, North Carolina.
Affinergy was awarded 2005 Technology Innovation of the Year by Frost & Sullivan in the category of Medical Device Coatings. The award cited the biofriendly system of Affinergy which has the potential to "become an industry standard" for medical device coatings.
"Affinergy looks forward to meeting new Partners and Investors from a broad spectrum of markets at the Investment in Innovation Conference," said Peyton Anderson, CEO of Affinergy. "We are experiencing rapid growth fueled by Partnerships, grant funding, and early in vivo successes. Over the past year, we have validated our systems in vitro and in vivo as well as secured multiple partnerships with large medical device companies. We look forward to expanding upon that strong foundation by forming new collaborations."
Affinergy's "Interfacial Biomaterials" (IFBMs) are modular structures that include 2 functional peptides:
-- one selectively binds to a specific biological material
-- one selectively binds to a target surface (biological or synthetic)
The two peptides are joined through a proprietary linker technology that offers unique capabilities such as cleavability or cross-linking. Affinergy is building and patenting a "library" of peptides that bind with high affinity and high selectivity to synthetic and bioactive materials that are widely used in the biomedical and therapeutic industries.
Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "Investment In Innovation" conference or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512, e-mail kristy@medtechinsight.com, or visit www.medtechinsight.com.
© 2005 Business Wire
